SEARCH

SEARCH BY CITATION

References

  • 1
    Clarke R, Peden JF, Hopewell JC et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 2009; 361: 251828.
  • 2
    Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 2009; 301: 23319.
  • 3
    Tregouet DA, Konig IR, Erdmann J et al. Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease. Nat Genet 2009; 41: 2835.
  • 4
    Kronenberg F, Utermann G. Lipoprotein(a): resurrected by genetics. J Intern Med 2013; 273: 630.
  • 5
    Berg K. A new serum type system in man–the Lp system. Acta Pathol Microbiol Scand 1963; 59: 36982.
  • 6
    Utermann G. The mysteries of lipoprotein(a). Science 1989; 246: 90410.
  • 7
    Berglund L, Ramakrishnan R. Lipoprotein(a): an elusive cardiovascular risk factor. Arterioscler Thromb 2004; 24: 221926.
  • 8
    Erqou S, Kaptoge S, Perry PL et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009; 302: 41223.
  • 9
    Erqou S, Thompson A, Di Angelantonio E et al. Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants. J Am Coll Cardiol 2010; 55: 21607.
  • 10
    Farrer M, Game FL, Albers CJ et al. Coronary artery disease is associated with increased lipoprotein(a) concentrations independent of the size of circulating apolipoprotein(a) isoforms. Arterioscler Thromb 1994; 14: 127283.
  • 11
    Lamon-Fava S, Marcovina SM, Albers JJ et al. Lipoprotein(a) levels, apo(a) isoform size, and coronary heart disease risk in the Framingham Offspring Study. J Lipid Res 2011; 52: 11817.
  • 12
    Rifai N, Ma J, Sacks FM et al. Apolipoprotein(a) size and lipoprotein(a) concentration and future risk of angina pectoris with evidence of severe coronary atherosclerosis in men: the Physicians' Health Study. Clin Chem 2004; 50: 136471.
  • 13
    Sandholzer C, Boerwinkle E, Saha N, Tong MC, Utermann G. Apolipoprotein(a) phenotypes, Lp(a) concentration and plasma lipid levels in relation to coronary heart disease in a Chinese population: evidence for the role of the apo(a) gene in coronary heart disease. J Clin Invest 1992; 89: 10406.
  • 14
    Sandholzer C, Saha N, Kark JD et al. Apo(a) isoforms predict risk for coronary heart disease. A study in six populations. Arterioscler Thromb 1992; 12: 121426.
  • 15
    Langer C, Tambyrayah B, Nowak-Gottl U. Testing for apolipoprotein(a) phenotype using isoelectric focusing and immunoblotting technique. Methods Mol Biol 2013; 992: 40712.
  • 16
    Marcovina SM, Hobbs HH, Albers JJ. Relation between number of apolipoprotein(a) kringle 4 repeats and mobility of isoforms in agarose gel: basis for a standardized isoform nomenclature. Clin Chem 1996; 42: 4369.
  • 17
    Siekmeier R, Marz W, Scharnagel H. Determination of lipoprotein(a): comparison of a novel latex enhanced immunoturbidimetric assay and an immunoradiometric assay. Lab Medizin 1996; 20: 2948.
  • 18
    Marcovina SM, Koschinsky ML, Albers JJ, Skarlatos S. Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: recent advances and future directions. Clin Chem 2003; 49: 178596.
  • 19
    Tsimikas S, Brilakis ES, Miller ER et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med 2005; 353: 4657.
  • 20
    Mora S, Kamstrup PR, Rifai N, Nordestgaard BG, Buring JE, Ridker PM. Lipoprotein(a) and risk of type 2 diabetes. Clin Chem 2010; 56: 125260.
  • 21
    Kronenberg F, Utermann G, Dieplinger H. Lipoprotein(a) in renal disease. Am J Kidney Dis 1996; 27: 125.
  • 22
    Rubin J, Paultre F, Tuck CH et al. Apolipoprotein [a] genotype influences isoform dominance pattern differently in African Americans and Caucasians. J Lipid Res 2002; 43: 23444.
  • 23
    Nordestgaard BG, Chapman MJ, Ray K et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 2010; 31: 284453.
  • 24
    Boden WE, Probstfield JL, Anderson T et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011; 365: 225567.
  • 25
    Carlson LA. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J Intern Med 2005; 258: 94114.
  • 26
    HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 2013; 34: 127991.
  • 27
    Cannon CP, Shah S, Dansky HM et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 2010; 363: 240615.
  • 28
    HPS3-TIMI55-REVEAL. Randomized Evaluation of the Effects of Anacetrapib Through Lipid-modification. http://clinicaltrials.gov/ct2/show/NCT01252953.
  • 29
    Jaeger BR, Richter Y, Nagel D et al. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nat Clin Pract Cardiovasc Med 2009; 6: 22939.